Madrigal Pharmaceuticals (MDGL) Is Down 7.5% After New Rezdiffra MASH Cardiometabolic Data Release – Has The Bull Case Changed?

Simply Wall St.06-04

In late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real‑world data at the EASL Congress showing its MASH drug Rezdiffra lowered cardiovascular risk markers, improved liver risk scores...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640315668?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-04 17:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640315668","market":"hk","top_or_hot":-1,"title":"Madrigal Pharmaceuticals (MDGL) Is Down 7.5% After New Rezdiffra MASH Cardiometabolic Data Release – Has The Bull Case Changed?","media":"Simply Wall St.","content":"<div>\n<p>In late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real‑world data at the EASL Congress showing its MASH drug Rezdiffra lowered cardiovascular risk markers, improved liver risk scores...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-is-down-75-after-new-rezdiffra\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Madrigal Pharmaceuticals (MDGL) Is Down 7.5% After New Rezdiffra MASH Cardiometabolic Data Release – Has The Bull Case Changed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMadrigal Pharmaceuticals (MDGL) Is Down 7.5% After New Rezdiffra MASH Cardiometabolic Data Release – Has The Bull Case Changed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-04 17:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-is-down-75-after-new-rezdiffra><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real‑world data at the EASL Congress showing its MASH drug Rezdiffra lowered cardiovascular risk markers, improved liver risk scores...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-is-down-75-after-new-rezdiffra\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-is-down-75-after-new-rezdiffra","article_id":"2640315668","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-is-down-75-after-new-rezdiffra","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640315668","pubTimestamp":1780565795,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real‑world data at the EASL Congress showing its MASH drug Rezdiffra lowered cardiovascular risk markers, improved liver risk scores in cirrhotic patients, and reduced liver stiffness in routine clinical practice.\nThese findings highlight Rezdiffra’s potential to address both liver disease progression and broader cardiometabolic risk, adding clinical depth beyond traditional histologic endpoints in MASH.\nWe’ll now examine...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4139":"生物科技"},"translate_title":"新的Rezdiffra MASH心脏代谢数据发布后，Madrigal Pharmaceuticals(MDGL)下跌7.5%——牛市情况发生变化了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1.5},"content_text":"In late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real‑world data at the EASL Congress showing its MASH drug Rezdiffra lowered cardiovascular risk markers, improved liver risk scores in cirrhotic patients, and reduced liver stiffness in routine clinical practice. These findings highlight Rezdiffra’s potential to address both liver disease progression and broader cardiometabolic risk, adding clinical depth beyond traditional histologic endpoints in MASH. We’ll now examine how this new evidence of Rezdiffra improving atherogenic lipid profiles could influence Madrigal’s wider investment narrative. Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.AdvertisementMadrigal Pharmaceuticals Investment Narrative RecapTo own Madrigal today, you need to believe Rezdiffra can become a foundational MASH therapy and that the company can manage high spending and rising competition. The EASL data reinforcing both liver and cardiovascular risk benefits appear supportive of the near term catalyst around broader clinical uptake and potential label expansion, while modestly easing (but not eliminating) concern that outcomes in more advanced F4c disease could disappoint. Among recent announcements, Madrigal’s new Phase 3 and real world evidence presented at EASL 2026 is most relevant here, because it ties directly to the key risk of dependence on Rezdiffra and the potential upside of expanding its use across the MASH spectrum. By strengthening the case that Rezdiffra improves atherogenic lipids and noninvasive liver markers, these data could influence how investors frame future outcomes readouts and payer discussions. Yet despite the encouraging data, investors should still be aware that... Read the full narrative on Madrigal Pharmaceuticals (it's free!)Madrigal Pharmaceuticals' narrative projects $2.5 billion revenue and $822.9 million earnings by 2028.Uncover how Madrigal Pharmaceuticals' forecasts yield a $671.07 fair value, a 37% upside to its current price.Exploring Other PerspectivesMDGL 1-Year Stock Price Chart While consensus focuses on Rezdiffra execution and spending risk, the most optimistic analysts were already assuming about US$3.6 billion of 2028 revenue and US$1.5 billion of earnings, so fresh EASL data could either reinforce or force a rethink of that far more ambitious view.Explore 6 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth 6% less than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Madrigal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.Contemplating Other Strategies?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Find 47 companies with promising cash flow potential yet trading below their fair value.We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640315668","isCrawlerRequest":true}